This study was conducted to obtain information on the tissue plasminogen
activator inhibitor-1 (PM-1) and fibrinogen levels in chronic renal
failure patients on regular hoemodialysis in a trial to find out any changes
that might contribute to thrombosis and bleeding.
This study was conduced on 40 chronic renal failure patients on regular
hemodialysis (HD) thrice weekly fow- hours each, with acetate based
dialysate for about 1-13 years prior to the study.
The study group consisted of 20 men and 20 women, 27 to 73 years
old. The hemodialysis prescription was 12 to 13.5 h/wk, with the use of
1.1 - to 1.3 m2 cuprophane hollow -fibre dialyser. The dialyzers were not
reused. In addition to 10 healthy volunteers with matched age and sex as
a control group.
The main causes of chronic renal failure were hypertensive glomerulosclerosis
and diabetic nephropathy disease in most of the patients.
All patients were anwic and under treatment by heparin on the dialysis
sessions ranging from 7500- 15000 IU.
Hemodialysis (HD) was peiformed with volumetrically controlled machines.
In our work the assessment of plasma fibrinogen levels in the study
group are significantly increase after hoPmodinl _Isis in comparison to before
hoemodialysis (Ps aan).
However plasma fibrinogen levels showed non significant change be-
tween shidy group and control group (P> 0.05).
In this study plasma plasminogen activator inhibitor -1 (PM-1) levels
revealed high significant decrease after haemodialysis in comparison to
before haPrnodialysis (P < 0.001).
Plasma plasminogen activator inhibitor-1 (PM-1) levels revealed significant
decrease before and after haemodialysis compared to controls (P <
0.001).
In conclusion: coagulation and fibrinolysis are enhanced on regular
haemodialysis treated (RD?) patients, a majority of patients on dialysis
are in a hemostatic disturbance state, which need careful adjustment of
an anticoagulant regimens, by the lowering of plasma level of tissue plasminogen
activator inhibitor-1 (tPAI-1), there is tendency to bleeding rather
than thrombosis in regular hnemodinl _Isis treatment patients. |
